HEALTH PROFESSIONAL · SOURCE READING

Signal transduction inhibitors

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease

Studies indicate that both BRAF and MEK inhibitors can significantly impact the natural history of melanoma, although they do not appear to be curative as single agents. Three combination regimens of BRAF and MEK inhibitors have improved PFS and OS compared with BRAF inhibitor monotherapy.

Continue within this section

BRAF inhibitors →MEK inhibitors →c-KIT inhibitors →Combination signal transduction inhibitor therapy →Combination signal transduction inhibitor therapy plus anti–PD-L1 therapy →

Preserved source evidence · Not medical advice